Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Avigdor

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Leukemia|July 30, 2002
Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysisA Shimoni, A Nagler, C Kaplinsky, et al.
Leukemia|October 14, 2006
Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cellsH Gal, N Amariglio, L Trakhtenbrot, et al.
Bone Marrow Transplantation|May 17, 2016
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantationP Tsirigotis, I Danylesko, K Gkirkas, et al.
Leukemia|March 11, 2017
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expressionM Abraham, S Klein, B Bulvik, et al.
Bone Marrow Transplantation|April 20, 2004
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapyJ Czyz, R Szydlo, W Knopinska-Posluszny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patientsJ Czyz, R Dziadziuszko, W Knopinska-Postuszuy, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Leukemia|July 30, 2002
Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysisA Shimoni, A Nagler, C Kaplinsky, et al.
Leukemia|October 14, 2006
Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cellsH Gal, N Amariglio, L Trakhtenbrot, et al.
Bone Marrow Transplantation|May 17, 2016
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantationP Tsirigotis, I Danylesko, K Gkirkas, et al.
Leukemia|March 11, 2017
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expressionM Abraham, S Klein, B Bulvik, et al.
Bone Marrow Transplantation|April 20, 2004
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapyJ Czyz, R Szydlo, W Knopinska-Posluszny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patientsJ Czyz, R Dziadziuszko, W Knopinska-Postuszuy, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Pageof 3